Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228078 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Protocol to SNK01-AD01 Study
A Phase 2 study of Alzheimer Disease, sponsored by NKGen Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07228078: Recruiting Phase 2 study of Alzheimer Disease, sponsored by NKGen Biotech.
NCT07228078 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by NKGen Biotech. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228078, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by NKGen Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-Label Extension Protocol to SNK01-AD01 Study
Primary Outcome
Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs
Conditions Studied
Interventions
- BIOLOGICAL SNK01
Study Locations (1)
California
- Behavioral Research Specialists, LLC - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT07228078 shows while recruiting
NCT07228078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which SNK01 is the first listed.
NCT07228078 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07228078 about?
NCT07228078 is a clinical study titled "Open-Label Extension Protocol to SNK01-AD01 Study". Open-Label Extension Protocol to SNK01-AD01 Study
What is the current status of trial NCT07228078?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-06-30. Estimated completion is 2028-04.
What conditions does trial NCT07228078 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT07228078?
The interventions under investigation include: SNK01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07228078?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228078 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228078's enrollment target sits among peer trials
30 239th of 306 higher than 56 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI